Conversely, extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of de novo cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk.
[URL unfurl="true"]https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2265.2005.02404.x#:~:text=Conversely%2C%20extensive%20studies%20of%20the%20outcome%20of%20GH,has%20revealed%20no%20increase%20in%20observed%20cancer%20risk.[/URL]
Giovannucci, E., Pollak, M.N., Platz, E.A., Willett, W.C., Stampfer,M.J., Majeed, N., Colditz, G.A., Speizer, F.E. & Hankinson, S.E.(2000) A prospective study of plasma insulin-like growth factor-1and binding protein-3 and risk of colorectal neoplasia in women.Cancer Epidemiology, Biomarkers & Prevention, 9, 345–349.
Conclusions: These results support earlier findings of increased risk of colon cancer in subjects with elevated plasma IGF-1. Our results however do not support the hypothesis that the risk of rectal cancer could also be directly related to IGF-1 levels.
[URL unfurl="true"]https://www.scirp.org/journal/paperinformation.aspx?paperid=81059[/URL]
In conclusion, our study corroborates evidence from previous studies showing that GH replacement therapy in AGHD patients would not increase the risk of cancer; instead, it might be even decrease cancer risk. The results suggested that GH replacement therapy in AGHD patients was safe.
